See how Ann's Fund is supporting Breast Cancer Research this year!
In 2023, The National Cancer Institute (NCI) distributed $7.1 billion dollars to various cancer initiatives.
According to a new study published in the JAMA Health Forum, the U.S. spends twice as much on cancer care than average for high-income countries but mortality rates are only slightly better than average for these countries.
Cancer is still the second leading cause of death in the US. The number of cancer cases is on the rise. It is now invading more young and middle aged people. According to the CDC 600,000 people will die from cancer this year. About 42,000 of those will be women with breast cancer.
The bottom line is that we don’t seem to be moving the needle very far or very quickly. Is Ann's Fund really making a difference?
Intent on using Ann's Fund to make a tangible difference in Breast Cancer, a fresh search began. Where is the young Elon Musk or Steve Jobs of cancer? The probe for an "out of the box" solution to revolutionary Breast Cancer Treatment led to a 78-year old professor on the 5th floor in the Department of Biology at Boston College. His name is Thomas Seyfried. He received a PhD in 1976 in genetics and neurochemistry from the University of Illinois at Urbana-Champaign, followed by a postdoctoral degree from Yale University in New Haven, Connecticut, in the field of neurochemistry and genetics.
Professor Seyfried has spent the last 30 years studying cancer. He has published over 200 peer-reviewed publications and written the groundbreaking book, Cancer as a Metabolic Disease: On the origin, Management, and Prevention of Cancer (John Wiley Press). His metabolic theory postulates that cancer cells must rely almost exclusively on glucose and glutamine “fermentation” for energy and dietary changes that severally reduce carbohydrate intake can effectively “starve” cancer cells.
There is a case study of a 47 year old woman from Ohio who was diagnosed with Breast Cancer in May of 2017.
Initially, she refused conventional chemotherapy because of its potential for side effects and toxicity.
However, in August of 2018, following extensive disease progression and deterioration of general health, she sought medical treatment. On re-evaluation, she was considered ineligible for conventional treatment due to her advanced end-stage disease, poor performance status, and advanced respiratory symptoms.
She obtained a second opinion and was informed that her expected prognosis was less than one month. That had a familiar ring…
Exploring other options, she was admitted to the ChemoThermia Oncology Center in Istanbul, Turkey in November of 2018. At that time, she weighed 84 pounds and had extensive metastatic disease with lesions in the brain, lungs, chest cavity, liver, abdomen, and bones.
She received a six-month treatment protocol comprised of:
The treatments eliminated all detectable lesions. The therapeutic response was sustained for two years with maintenance treatment comprising KD, dietary supplements, and repurposed medications.
This single case report presents evidence of a complete and durable response to a treatment protocol combining MSCT and a novel metabolic therapy in a patient with end-stage breast cancer.
A photo of her (smiling) was taken in October of 2024 indicates she is still outliving her predictions.
Had Ann known about this, there is no doubt she would have locked up the house and boarded a plane to Istanbul.
In 2025, Ann’s fund is sponsoring a preclinical trial called Targeting Glucose and Glutamine for the Metabolic Management of Breast Cancer. The principal investigator is Thomas N. Seyfried, Ph. D. from Boston College.
Meet professor Seyfried and get insight into his motivation for making a difference in cancer research.
Professor Seyfried explains why he believes cancer is a Metabolic disease and must be treated as such.